InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal
STOCKHOLM, Feb. 25, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company's lead drug candidate in development for the treatment of moderate to severe ulcerative colitis. The paper, pu...
InDex Pharmaceuticals' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results and Supports the Strategy Going Forward
STOCKHOLM, Feb. 20, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose optimisation study CONDUCT, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate...
InDex Pharmaceuticals Meets Primary Endpoint in the Phase IIb Study CONDUCT with Cobitolimod in Ulcerative Colitis
STOCKHOLM, Aug. 27, 2019 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced positive top line results from the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint of cl...
